P Lederlin
- Pathology and Forensic Medicine top 0.05%
- Lymphoma Diagnosis and Treatment 38
- Genetics top 0.2%
- Chronic Lymphocytic Leukemia Research 22
- Neurology top 0.5%
- CNS Lymphoma Diagnosis and Treatment 8
- Oncology top 0.5%
- Viral-associated cancers and disorders 8
- Hematology top 2%
- Multiple Myeloma Research and Treatments 5
-
- Lung Cancer Treatments and Mutations 11
-
- Acute Lymphoblastic Leukemia research 9
-
- Hematological disorders and diagnostics 6
In The Last Decade
P Lederlin
74 papers receiving 6.3k citations
Hit Papers
Peers
Comparison fields: 5 of 106
- Pathology and Forensic Medicine 5.1k
- Genetics 2.0k
- Neurology 1.9k
- Oncology 3.3k
- Hematology 448
Countries citing papers authored by P Lederlin
This map shows the geographic impact of P Lederlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P Lederlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P Lederlin more than expected).
Fields of papers citing papers by P Lederlin
This network shows the impact of papers produced by P Lederlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P Lederlin. The network helps show where P Lederlin may publish in the future.
Co-authorship network
The 25 scholars most cited alongside P Lederlin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 90yttrium Ibritumomab Tiuxetan (zevalin) Combined With Beam (z-beam) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed Or Refractory Follicular Lymphoma. a Gela Phase Ii Prospective Study | 2009 | 1 |
| 2 | 2007 | 5 | |
| 3 | 2004 | 22 | |
| 4 | 2003 | 32 | |
| 5 | 2003 | 80 | |
| 6 | CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphomabreakdown → | 2002 | 3976 |
| 7 | 2000 | 17 | |
| 8 | High efficacy of recombinant urate oxidase in prevention of renal failure related to tumor lysis syndrome (TLS). | 1998 | 9 |
| 9 | Late intensification is superior to early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma. A randomized study from the GELA: LNH RP93. | 1997 | 1 |
| 10 | Superiority of late over early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma: A randomized study from the GELA: LNH RP 93 | 1997 | 7 |
| 11 | 1996 | 25 | |
| 12 | 1996 | 3 | |
| 13 | 1995 | 18 | |
| 14 | 1995 | 18 | |
| 15 | [Lymphoproliferative syndromes after cardiac transplantation and treatment with cyclosporine. Report of 4 cases]. | 1992 | 3 |
| 16 | 1992 | 25 | |
| 17 | Intérêt des hautes doses de cytosine-arabinoside dans le traitement des leucémies aiguës résistantes. | 1987 | 1 |
| 18 | [High-dose Cytosine-arabinoside for the Treatment of Resistant Acute-leukemia] | 1987 | 2 |
| 19 | 1984 | 2 | |
| 20 | 1980 | 20 |
About P Lederlin
P Lederlin is a scholar working on Genetics, Pathology and Forensic Medicine and Microbiology, having authored 76 papers that have together received 6.5k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (38 papers), Chronic Lymphocytic Leukemia Research (22 papers), Lung Cancer Treatments and Mutations (11 papers), Acute Lymphoblastic Leukemia research (9 papers), CNS Lymphoma Diagnosis and Treatment (8 papers), Viral-associated cancers and disorders (8 papers), Hematological disorders and diagnostics (6 papers) and Multiple Myeloma Research and Treatments (5 papers). The work is most often cited by research in Pathology and Forensic Medicine (5.1k citations), Genetics (2.0k citations) and Neurology (1.9k citations). P Lederlin has collaborated with scholars based in France, Belgium and Nigeria. Frequent co-authors include Hervé Tilly, Éric Lepage, Bertrand Coiffier, Josette Brière, Christian Gisselbrecht, Félix Reyes, Philippe Gaulard, Pierre Morel, Gilles Salles and Raoul Herbrecht. Their work appears in journals such as Journal of Clinical Oncology, Blood, Cancer, Annals of Oncology and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.